A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors NYU #s23-01065

Brief description of study

This study wants to try out a new treatment called DB-1305,a TROP2 Antibody Drug Conjugate (ADC) for advanced solid tumors. The study team will test different amounts of it alone and possibly with another medicine called pembrolizumab. In the first part of the study, patients will take part to figure out the highest amount of DB-1305 to use with the least amount of side effects. Then, in the second part, more patients will join in smaller groups to see how well DB-1305 works for specific types of tumors. The study team will check if there are few side effects, how the body handles it, and if it helps treat the cancer. They also want to find out if certain things in a person's body (biomarkers) can show how well the treatment might work or how the body reacts to it.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.